From Nasdaq: 2025-04-15 08:17:00

Bristol Myers Squibb (BMY) faced a setback in the ODYSSEY-HCM study for Camzyos, a cardiovascular drug for non-obstructive hypertrophic cardiomyopathy. The phase III trial did not meet its endpoints, causing BMY stock to drop in after-hours trading. Sales of Camzyos were $602 million in 2024.

The study enrolled 580 adult patients to test the efficacy of Camzyos in nHCM. While disappointing results were observed, no new safety concerns arose. Cytokinetics, Inc. (CYTK) also experienced a drop in after-hours trading due to concerns about cardiac myosin inhibitors’ efficacy in nHCM.

BMY’s Growth Portfolio, including drugs like Reblozyl, Breyanzi, and Opdivo, has stabilized revenue amid generic competition. FDA approvals for drugs like Opdivo Qvantig and Cobenfy for schizophrenia have expanded BMY’s portfolio. The acquisition of 2seventy Bio, Inc. for $286 million also strengthens their position in the market.

Bristol Myers currently holds a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Amicus Therapeutics, Inc. (FOLD) and ANI Pharmaceuticals, Inc. (ANIP), both with a Zacks Rank #1 (Strong Buy). Estimates for both companies’ EPS have shown promising growth in 2025 and 2026, with positive earnings surprises in recent quarters.

ANI Pharmaceuticals has seen a 24.3% rally in shares year to date, with earnings beating estimates consistently. Amicus Therapeutics has shown a 45.42% average earnings surprise. Both companies offer strong potential for growth in the biotech sector. Consider these stocks for potential investment opportunities.

Experts have identified 7 elite stocks with strong potential for early price pops. These hand-picked stocks have historically outperformed the market, with an average gain of +23.9% per year since 1988. Stay ahead of the market by exploring these top stock picks now.



Read more at Nasdaq: BMY Down on Heart Drug Camzyos Failure in Late-Stage Study